Clinical trials: Hematologic
Acute Lymphoblastic Leukemia
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel).
- Trial name
- KareALL (NCT07039383)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the…
- Trial name
- NCT00642954
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e.
- Conditions
- Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT04688853
- Testing
- TEG002
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gadeta B.V.
Hematologic Neoplasms, Neoplasms
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous infusions in patients with refractory solid or hematologic malignancies.
- Trial name
- NCT00473577
- Testing
- CRA-24781
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Pharmacyclics LLC.
Acute Myeloid Leukemia
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly diagnosed AML who are unfit for intensive…
- Trial name
- NCT04038437
- Testing
- CPX-351, Venetoclax
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
The purpose of the phase 1b/2 study is to determine whether Onvansertib given orally daily for 5 consecutive days every 28 days is safe and tolerable in adult patients who have relapsed/refractory Acute Myeloid Leukemia (AML), or…
- Trial name
- NCT03303339
- Testing
- Onvansertib, Cytarabine, Decitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology
Sepsis Associated Disseminated Intravascular Coagulation (DIC)
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
This study is designed to evaluate a new investigational drug, BAY 3389934, in healthy Japanese volunteers. The primary purpose is to see how safe the drug is and how well it is tolerated by the body when given at different…
- Trial name
- NCT07176728
- Testing
- BAY 3389934
- Where
- 2 sites in Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Bioequivalence
A Pilot Bioequivalence Study of Pomalidomide
Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.
- Trial name
- NCT03424928
- Testing
- Pomalidomide 4 MG Oral Capsule, Pomalidomide 4 MG Oral Capsule-Pomalyst
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Lymphoma, Hodgkin's Lymphoma
Pegfilgrastim PBPC Mobilization Study
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize…
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology
- Trial name
- NCT00066092
- Testing
- pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg
- Volunteers
- 41 people
- Sponsor
- Amgen
Healthy Volunteers, Sickle Cell Disease
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias.
- Trial name
- NCT03815695
- Where
- 18 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Forma Therapeutics, Inc.
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma.
- Trial name
- NCT00655837
- Testing
- SGN-40, rituximab, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Tumor Lysis Syndrome
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
The purpose of this study is to determine whether febuxostat is superior to allopurinol in the prevention of tumor lysis syndrome (TLS) in patients with hematological malignancies at intermediate or high risk of TLS (according to…
- Trial name
- FLORENCE (NCT01724528)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 346 people
- Sponsor
- Menarini Group
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
This study evaluates ADCT-301 in participants with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). Participants will participate in a dose-escalation phase (Part 1) and receive ADCT-301 either weekly or once…
- Trial name
- NCT02588092
- Testing
- ADCT-301
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- ADC Therapeutics S.A.
Anemia, Blood Transfusion
A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.
The purpose of this study is to determine an effective dose of epoetin alfa to be administered prior to surgery, to decrease the need for blood transfusions during hip replacement.
- Conditions
- Anemia, Blood Transfusion, Orthopedic Surgery
- Trial name
- NCT00269971
- Testing
- epoetin alfa
- Sponsor
- Janssen-Ortho Inc., Canada
Thrombocytopenia
Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State
The overall design of this clinical study is a single center, randomized, open label, single dose, two sequence, two cycle bioequivalence trial in healthy individuals under fasting conditions.
- Trial name
- NCT06768632
- Testing
- Group 1: single-dose of test formulation+single-dose of reference formulation, Group 2: single-dose of reference formulation+single-dose of test formulation
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Beta-Thalassemia
A Long-term Follow-up Study in Participants Who Received CS-101
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
- Trial name
- NCT06685536
- Testing
- Safety and efficacy assessments
- Where
- China
- Volunteers
- 5 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Chemotherapy-induced Symptomatic Anemia, Solid Tumors
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
- Conditions
- Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas
- Trial name
- ORHEO (NCT02140736)
- Testing
- Epoetin biosimilar
- Where
- 172 sites in France
- Volunteers
- 2,333 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Haemophilia A, Haemophilia B
Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
The purpose of the study is to investigate the safety and effectiveness of Alhemo in participants under real-world clinical practice in Japan. Total duration of this study is about 6 years.
- Trial name
- NCT06831734
- Testing
- Concizumab
- Where
- 23 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.